News | March 23, 2008

AdvanDx Receives Frost and Sullivan’s Rapid In-Vitro Diagnostic Innovation of the Year Award

March 24, 2008 – AdvanDx received Frost and Sullivan’s 2008 Technology Innovation of the Year Award in the field of rapid in-vitro molecular diagnostic technology with its PNA FISH, which is used by hospitals to quickly identify bloodstream pathogens in hours instead of days.

The rapid PNA FISH results enable laboratories to report critical information to physicians and pharmacists earlier to ensure optimal therapy and help reduce mortality rates for patients afflicted with bloodstream infections, the company said.

Frost and Sullivan’s team of industry analysts conducted more than 400 hours of analysis in the diagnostics market.

“During the process of conducting the research, it became clear that AdvanDx would be a strong candidate to receive the in-vitro molecular diagnostic technology innovation of the year award,” said Abhishek Dutta, research analyst, Frost and Sullivan. “PNA FISH is an extremely innovative technology platform that prevents the unnecessary use of drugs, enables doctors to make rapid diagnoses, treat patients sooner, save lives and significantly reduce costs throughout all areas of the hospital. As a result, AdvanDx is diversifying into new product lines that will enable the firm to explore new, multi-billion dollar in-vitro diagnostic markets.”

To choose The Technology Innovation of the Year Award recipient, Frost and Sullivan’s analyst team conducted a selection process that included primary interviews and extensive primary and secondary research via a bottom-up approach. The analyst team considered AdvanDx’s pace of research and technology innovation and its significance and relevance to the overall industry. The ultimate award recipient was selected after a thorough evaluation of this research.

The recipient of the award has excelled based on the following criteria:

- Significance of AdvanDx’s technology in the industry
- Potential of AdvanDx’s technology/products to become an industry standard
- Competitive advantage of AdvanDx’s technology when compared to competing technologies
- Ease of adoption of AdvanDx’s technology
- Breadth of intellectual property related to the innovation (e.g., patents, coverage in scientific publications, papers and in peer reviewed articles).

For more information:,

Related Content

pre-operative testing, NYU Langone, guidelines
News | June 09, 2015
Professional physician associations consider certain routine tests before elective surgery to be of low value and high...
News | March 26, 2015
March 26, 2015 — Siemens Healthcare introduced a new angiography system and new cardiac ultrasound apps at the 2015...
Nephrocheck Test System, Blood testing, contrast media

Image courtesy of Astute Medical

News | January 27, 2015
Ortho-Clinical Diagnostics Inc. announced the nationwide availability to hospitals of the Nephrocheck Test System...
blood testing, nephrocheck
News | September 30, 2014
The U.S. Food and Drug Administration has allowed marketing of the NephroCheck test, a first-of-a-kind laboratory test...
News | June 15, 2008
June 16, 2008 - 3M Health Care said today its 3M Rapid Detection Flu A B Test demonstrated better clinical and analyt
News | March 11, 2008
March 12, 2008 - Neoteric Technology Ltd.
News | February 25, 2008
February 26, 2008 - Masimo announced it would debut its technology for noninvasive and continuous total hemoglobin (S
News | February 04, 2008
February 5, 2008 - Patients with diabetes, cardiac problems, kidney disorders or high blood pressure could benefit fr
News | January 13, 2008
January 14, 2008 – A new, hand-held creatinine monitoring system, Nova StatSensor Creatinine, was released last week
News | January 10, 2008
January 11, 2008 - Washington Hospital Center took a major step forward this week in the federally funded Project ER